A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy.

ABSTRACT:

Background

In observational studies, higher uric acid levels are associated with metabolic syndrome, diabetes, and kidney disease.

Objective

The objective of this study is to examine whether reduction of plasma uric acid with febuxostat, a xanthine oxido reductase inhibitor, impacts adipose tissue oxidative stress, adipokines, and markers of systemic inflammation or kidney fibrosis.

Design

This was a double-blinded randomized controlled trial.

Setting

Academic university setting was used.

Patients

Overweight or obese adults with hyperuricemia and type 2 diabetic nephropathy were included.

Measurements

Adipose tissue thiobarbituric acid reducing substances (TBARS) and adiponectin concentrations and urinary transforming growth factor-β (TGF-β) were

SUBMITTER: Beddhu S 

PROVIDER: S-EPMC5332087 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature